TIBOLA : Multicenter Descriptive Study in Eastern France

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05458245

Enrollment

Registered

2022-07-14

Start date

2022-06-01

Completion date

2023-06-01

Last updated

2022-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rickettsia Infections, TIBOLA

Keywords

dermacentor, DEBONEL

Brief summary

TIBOLA (TIck-BOrne LymphAdenopathy) is a tick-borne disease. The pathogen is most often rickettsia (R. slovaca or R. raoultii), but other strict intracellular bacteria have been described (Francisella tularensis, Coxiella burnetii, Bartonella hensenlae). Transmitted by ticks (Dermacentor), it is characterized by an inoculation eschar at the tick bite site, accompanied by painful loco-regional lymphadenopathy. It is most often a benign pathology, which can nevertheless leave sequellar alopecia or persistent asthenia. In spring 2021, an impression of increased cases was reported by clinicians in Eastern France. The study aims to clarify the clinical-biological presentation and the evolution of the number of cases of TIBOLA in this region between 2016 and 2021. At the same time, entomologists have noted an upsurge in this tick in certain biotopes in recent years.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Person, minor or major, * having been diagnosed with TIBOLA * between January 1, 2016 and December 31, 2021 * at the University Hospital of Nancy or Strasbourg in the departments of infectious and tropical diseases, dermatology, microbiology and pediatrics.

Design outcomes

Primary

Measure	Time frame
Number of cases of TIBOLA	baseline

Secondary

Measure	Time frame	Description
Characteristics of tick bites	baseline	frequency, location, date
Frequency of the various symptoms and clinical signs of the disease	baseline	inoculation ulcer, alopecia, lymphadenopathy, asthenia, fever, rash, headache, arthromyalgia, pruritus, facial oedema, other
Epidemiological and demographic characteristics	baseline	gender, age, habitat, hobbies, occupation
Treatment	baseline	nature, efficiency
Entomological analysis	evolution between 2016 and 2021	respective proportion of Dermacentor and Ixodes encountered on the territory. Detection by molecular biology of the presence of Rickettsia spp. in ticks
Biological results	baseline	serology and PCR of rickettsia, non-specific abnormalities

Countries

France

Outcome results